UBS O'Connor’s Decibel Therapeutics, Inc. Common Stock DBTX Stock Holding History

UBS O'Connor’s Portfolio DBTX Stock Details DBTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-199,200	Closed	-$767K	–	673
2023 Q2	$767K	Buy	199,200 +9,814	+5%	+$36K	0.02%	406
2023 Q1	$572K	Buy	189,386 +1,420	+0.8%	+$4.91K	0.01%	456
2022 Q4	$385K	Buy	187,966 +30,221	+19%	+$92.1K	0.01%	630
2022 Q3	$546K	Buy	157,745 +70,000	+80%	+$319K	0.01%	806
2022 Q2	$369K	Buy	+87,745	New	+$207K	﹤0.01%	829

Other funds holding DBTX

ACA

Atlas Capital Advisors Jackson, Wyoming $914M AUM

UBS O'Connor's DBTX Position: Q3 2023 in Review

UBS O'Connor sold out of Decibel Therapeutics, Inc. Common Stock (DBTX) in Q3 2023, closing a stake of 199,200 shares — an estimated $767K sold.

UBS O'Connor first reported a position in DBTX in Q2 2022 and held it in 5 quarters. The position peaked at $767K in Q2 2023. 1 fund tracked by Wall St. Rank holds DBTX as of Q3 2023.

UBS O'Connor reported no remaining Decibel Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
UBS O'Connor sold 199,200 Decibel Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $767K.
UBS O'Connor first reported a position in Decibel Therapeutics, Inc. Common Stock in Q2 2022 and held it in 5 quarters.
UBS O'Connor's Decibel Therapeutics, Inc. Common Stock position peaked at $767K in Q2 2023.
1 fund tracked by Wall St. Rank held Decibel Therapeutics, Inc. Common Stock as of Q3 2023.

Based on UBS O'Connor's 13F filing for Q3 2023, filed 14 Nov 2023.